ProfileGDS5678 / 1428162_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 87% 90% 88% 87% 87% 75% 85% 85% 85% 85% 89% 85% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4744986
GSM967853U87-EV human glioblastoma xenograft - Control 26.7746387
GSM967854U87-EV human glioblastoma xenograft - Control 37.2593990
GSM967855U87-EV human glioblastoma xenograft - Control 47.087288
GSM967856U87-EV human glioblastoma xenograft - Control 56.6974287
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3745787
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9258575
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3135985
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3305985
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4294885
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2833985
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0132789
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2988485
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5056186